Phase 2 N=26 Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Multiple Myeloma
Primary: Maximum Tolerated Dose (Phase 1) — 0; 1; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities
Kawasaki Disease
Primary: Number of Participants With SAE — 4 Participants
Phase 2 N=298 Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 25.11; 25.12; 25.35; 25.99 mmHg — p=<0.0001
Phase 2 N=169 Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Warts
Primary: Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit — 16; 29; 31; 29 Participants — p=0.0329
Phase 2 N=18 Buprenorphine Used With Treatment Resistant Depression in Older Adults
Major Depressive Disorder · Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — -1; -5.3; 21.3; 15.3 units on a scale
Phase 2 N=405 Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD
Primary: Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4 — 0.203; 0.209; 0.257; 0.196 Liters — p=<0.001
Phase 2 N=185 A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
Influenza
Primary: Humoral Immune Response for A/Indonesia/05/2005 (H5N1) Strain in Terms of Vaccine-homologous Haemagglutination Inhibition (HI) Antibody Titers Following Primary…
Phase 2 N=16 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma
Relapsed Ewing Sarcoma · Refractory Ewing Sarcoma
Primary: Number of Participants With a Metabolic Response as Evaluated by PERCIST v1.0 — 1; 2; 4; 3 Participants
Phase 2 N=42 A Study of LY2623091 in Male and Females With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change From Baseline to Day 21 in Proteinuria Based on 24-hours Pooled Urine — -98.9; -19.7; 119.4; 273.7 milligrams/24 hours (mg/24 h)
Phase 2 N=117 An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Multiple Myeloma
Primary: Progression Free Survival (PFS) — 10.25; 4.70 Months — p=0.0043
Phase 2 N=46 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
Huntington's Disease
Primary: Number of Participants With Treatment-related Adverse Events (TEAEs) — 12; 3; 6; 6 Participants
Phase 2 N=159 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)
Ankylosing Spondylitis (AS)
Primary: Percentage of Patients Who Achieved Assessment of Spondyloarthritis International Society (ASAS) 40 Improvement Criteria at Week 12. — 17.5; 25.0; 20.5; 15.0 Percentage…
Phase 2 N=294 Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
Intracerebral Hemorrhage
Primary: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days — 48; 47 Participants
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
Phase 2 N=185 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis
Arthritis, Psoriatic
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16 — 35.7; 57.1; 61.9; 59.0 percentage of participants — p=0.007